RenovoRx (NASDAQ: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, has closed its underwritten initial public offering of 1,850,000 units at a public offering price per unit of $9.00. According to the update, RenovoRx offered all of the units, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock. The warrants have a $10.80 exercise price per share and are exercisable for a period of five years after the issuance date. In addition, RenovoRx granted the underwriters a 45-day option to purchase up to an additional 277,500 shares of its common stock, and/or warrants to purchase up to an additional 277,500 shares of its common stock, at the initial public offering price, less underwriting discounts and commissions. RenovoRx’s common stock was approved for listing on The Nasdaq Capital Market under the ticker symbol RNXT in connection with the offering, which closed on Aug. 30, 2021. Roth Capital Partners acted as sole book-running manager for the offering.
To view the full press release, visit https://ibn.fm/eFfwg
About RenovoRx Inc.
RenovoRx, a biopharmaceutical company headquartered in Silicon Valley, California, has developed a therapy platform targeting difficult-to-treat tumors. Targeted therapy via the proprietary RenovoRx Trans-Arterial Micro-Perfusion (“RenovoTAMP”) platform safely and without transmission to non-targeted areas, is the primary focus. RenovoRx’s portfolio includes seven U.S. patents for its technology. The company also has secured two separate Orphan Drug Designations from the FDA for intra-arterial gemcitabine including pancreatic and bile duct cancers. The RenovoTAMP therapy is being studied in the phase III TIGeR-PaC trial for the treatment of locally advanced pancreatic cancer. For more information, please visit www.RenovoRX.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
